We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-9.21%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$617M
AUM Growth
-$114M
Cap. Flow
-$1.09M
Cap. Flow %
-0.18%
Top 10 Hldgs %
74.33%
Holding
32
New
6
Increased
3
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$9.05M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$7.74M
3
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$6.69M
4
ALT icon
Altimmune
ALT
+$5.59M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.66M

Top Sells

Rank Stock Value
1
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$13.7M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$7.64M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$6.53M
4
CVRX icon
CVRx
CVRX
+$6.52M
5
AKYA
Akoya BioSciences
AKYA
+$6.12M

Sector Composition

Rank Sector Weight
1 Healthcare 95.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JBIO
26
Jade Biosciences
JBIO
$1.2B
$2.77M 0.45%
+4,315
New +$1.67M
SVRA icon
27
Savara
SVRA
$1.12B
$2.5M 0.4%
+1,905,265
New +$2.3M
AKYA
28
DELISTED
Akoya BioSciences
AKYA
– –
-400,000
Closed -$6.12M
CRVS icon
29
Corvus Pharmaceuticals
CRVS
$1.12B
– –
-250,000
Closed -$603K
CVRX icon
30
CVRx
CVRX
$137M
– –
-533,370
Closed -$6.52M
OLMA icon
31
Olema Pharmaceuticals
OLMA
$1B
– –
-816,651
Closed -$7.64M
KNTE
32
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-773,014
Closed -$13.7M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q1 2022 Portfolio in Review

As of Q1 2022, VR Adviser held 32 positions worth $617M, down 16% from $732M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

VR Adviser's Q1 2022 filing shows 6 new, 3 increased, 2 reduced and 5 closed positions. Its largest new stake was Eiger BioPharmaceuticals, Inc.: 48,992 shares worth $12.2M. The largest sale was Kinnate Biopharma Inc. Common Stock, an estimated $13.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier.

  • VR Adviser's largest Q1 2022 buy was Eiger BioPharmaceuticals, Inc.: 48,992 shares worth $12.2M.
  • VR Adviser added most to Tricida, Inc. Common Stock in Q1 2022, an estimated $9.05M increase.
  • VR Adviser's biggest Q1 2022 reduction was Centessa Pharmaceuticals, cutting an estimated $6.53M.
  • VR Adviser fully exited Kinnate Biopharma Inc. Common Stock in Q1 2022, selling an estimated $13.7M.
  • VR Adviser's ten largest holdings make up 74% of its $617M portfolio in Q1 2022.
  • VR Adviser opened 6 new positions and closed 5 in Q1 2022.
  • VR Adviser's portfolio value fell 16% quarter-over-quarter to $617M.

Based on VR Adviser's 13F filing for Q1 2022, filed 16 May 2022.